



CASE REPORT

Splenic Infarction in a Case of Acute Promyelocytic Anemia

Nasim Valizadeh*

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article History:

Received: 13.12.2015

Accepted: 07.02.2016

Keywords:

Splenic infarction

Acute promyelocytic anemia

Hematological malignancies

*Corresponding author:

Nasim Valizadeh, MD;

Address: Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

Tel: +98 912 5474755

Fax: +98 21 88004140

Email: nsedaha0@gmail.com

ABSTRACT

Splenic infarction occurs due to occlusion of splenic vessels that leads to splenic tissue ischemia and necrosis. There are several reports regarding splenic infarction in patients with acute myelogenous leukemia (AML). Herein, we report a case of acute promyelocytic anemia (AML-M3) who presented with abdominal pain and splenic infarction.

Please cite this article as: Valizadeh N. Splenic Infarction in a Case of Acute Promyelocytic Anemia. IJBC 2016; 8(1): 23-24.

Introduction

Splenic infarction occurs due to occlusion of splenic vessels that leads to splenic tissue ischemia and necrosis.¹⁻⁴ There are several reports regarding splenic infarction in patients with acute myelogenous leukemia (AML). Here in, we report a case of acute promyelocytic anemia (AML-M3) who presented with abdominal pain and splenic infarction.

Case Presentation

The patient was a previously healthy 20-year-old woman who presented with blurred vision, abdominal pain and dizziness following hemorrhoid surgery. Physical examination revealed pallor, wide peripapillary retinal hemorrhage and splenomegaly. Blood examination on admission revealed: WBC; $54 \times 10^9/\mu\text{L}$, Hb; 7 gr/dl and Platelet count; $16 \times 10^9/\mu\text{L}$, LDH; 3300 IU/L (normal range up to 480), Prothrombin time (PT); 19.3 sec (12-15), INR; 1.67(1-1.2), Partial thromboplastin time (PTT); 28 sec (24-45), Fibrinogen level; 287 mg/dl (200-400), Fibrin

degradation product (FDP)>20 mg/L (reference range less than 10 mg/L) and D dimer >2000 ng/ml (normal <255). The Patient underwent bone marrow aspiration and biopsy which revealed hypercellular marrow with more than 95% blasts and in spite of mostly abnormal promyelocytes compatible with AML-M3. Flowcytometry revealed blasts positive for CD33, CD117 and negative for HLA-DR, myeloperoxidase staining of the blasts were strongly positive. Molecular genetic study revealed PML-RAR- α positivity by RT-PCR. Abdominal ultrasound showed splenomegaly (spleen size: 165×90 mm) with heterogeneous echo and large peripheral hypoechoic geographic lesions suggestive for infarction. Abdominal spiral CT scan showed splenic enlargement with extensive peripheral hypodensity and lack of contrast enhancement in favor of infarction (figure 1). Chemotherapy with daunorubicin, All-trans retinoic Acid (ATRA) and arsenic trioxide was initiated for the patient. He also received FFP and platelet transfusions considering the patients' conditions and diagnosis of the patient. Initially, the




Figure 1: splenomegaly with extensive hypodensity in favor of splenic infarction.

patient underwent supportive care and close observation for management of the splenic infarction. Finally, surgical consultation was conducted on day 28 after induction of remission which splenectomy was recommended due to persistence of large splenic lesions on serial abdominal imaging but did not perform due to thrombocytopenia.

Discussion

In our patient with AML-M3, disseminated intravascular coagulation (DIC) in the spleen led to splenic infarction. Splenic infarction is defined as occlusion of the splenic vessels that leads to splenic ischemia and necrosis which may be total or segmental. A heterogeneous group of diseases cause splenic infarction, mostly attributable to hematological malignancies and myeloproliferative disorders. However, benign hematological disorders such as autoimmune hemolytic anemia, hypercoagulable states, vascular disorders, trauma and iatrogenic etiologies such as pancreatotomy and liver transplant can also be influential.¹⁻⁸ Acquired protein C deficiency has been reported in AML.^{9,10} Splenic infarction alone is not an indication for surgery and requires close follow-up. Surgery is indicated for persistent symptoms or subsequent complications such as hemorrhage, rupture, and abscess formation. Our explanation for splenic infarction in this case of AML-M3 was thrombotic complication due to AML and its inherent thrombotic tendency as disseminated intravascular coagulation.

Conflict of Interest: None declared.

References

1. Antopolsky M, Hiller N, Salameh S, Goldshtein B, Stalnikowicz R. Splenic infarction: 10 years of experience. *Am J Emerg Med.* 2009; 27: 262–26.
2. Horeau J, Robin C, Guenel J, Nicolas G. An unusual complication of acquired hemolytic anemia, splenic infarction. *Concours Med.* 1963; 85:663–666.
3. Tzanck A, Andre R, Dreyfus B. Acquired hemolytic anemia with infarct of the spleen; splenectomy; recovery. *Bull Mem Soc Med Hop Paris.* 1951;67:286–290.
4. Park MY, Kim JA, Yi SY, Chang SH, Um TH, Lee HR. Splenic infarction in a patient with autoimmune hemolytic anemia and protein C deficiency. *Korean J Hematol.* 2011;46(4):274-8.
5. Arnold MH, Schrieber L. Splenic and renal infarction in systemic lupus erythematosus: association with anticardiolipin antibodies. *Clin Rheumatol.* 1988;7(3):406-10.
6. Miller LA, Mirvis SE, Shanmuganathan K, Ohson AS. CT diagnosis of splenic infarction in blunt trauma: imaging features, clinical significance and complications. *Clin Radiol.* 2004;59(4):342-8.
7. Hayashi H, Beppu T, Okabe K, et al. Risk factors for complications after partial splenic embolization for liver cirrhosis. *Br J Surg.* 2008;95(6):744-50.
8. Wu SC, Chen RJ, Yang AD, et al. Complications associated with embolization in the treatment of blunt splenic injury. *World J Surg.* 2008 Mar. 32(3):476-82.
9. Farah RA, Jalkh KS, Farhat HZ, Sayad PE, Kadri AM. Acquired protein C deficiency in a child with acute myelogenous leukemia, splenic, renal, and intestinal infarction. *Blood Coagul Fibrinolysis.* 2011; 22:140–143.
10. Troy K, Essex D, Rand J, Lema M, Cuttner J. Protein C and S levels in acute leukemia. *Am J Hematol.* 1991;37:159–162.